

wherein

$R^1$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{3-6}$ -cycloalkyl,  $C_{1-6}$ -alkoxy, halogen,  $-CF_3$ , or  $-OCF_3$ ;

$R^2$  is  $-NR^6R^7$ , wherein

$R^6$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{3-6}$ -cycloalkyl, or  $C_{2-4}$ -acyl,

$R^7$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{3-6}$ -cycloalkyl, or  $C_{2-4}$ -acyl, or

$R^6$  and  $R^7$  together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by  $C_{1-4}$ -alkyl, or  $R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;

$R^3$  is hydrogen, halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy,  $-CF_3$ , or  $-OCF_3$ ;

$R^4$  is hydrogen, halogen or  $C_{1-6}$ -alkyl; and

$R^5$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy, halogen,  $-CF_3$ , or  $-OCF_3$ ;

or a pharmaceutically acceptable salt thereof.--

--22. (new) The compound of the formula II according to claim 21, wherein:

$R^1$  is hydrogen,  $C_{1-4}$ -alkyl, cyclopropyl,  $C_{1-4}$ -alkoxy, halogen,  $-CF_3$ , or  $-OCF_3$ ;

$R^2$  is  $-NR^6R^7$ , wherein

$R^6$  is hydrogen,  $C_{1-4}$ -alkyl,  $C_{3-6}$ -cycloalkyl, or acetyl,

$R^7$  is hydrogen,  $C_{1-4}$ -alkyl,  $C_{3-6}$ -cycloalkyl, or acetyl, or

$R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;

$R^3$  is hydrogen, halogen,  $C_{1-4}$ -alkyl,  $C_{1-4}$ -alkoxy,  $-CF_3$ , or  $-OCF_3$ ;

$R^4$  is hydrogen,  $C_{1-4}$ -alkyl, or halogen; and,

$R^5$  is hydrogen,  $C_{1-4}$ -alkyl,  $C_{1-4}$ -alkoxy, halogen,  $-CF_3$ , or  $-OCF_3$ ;

or a pharmaceutically acceptable salt thereof.--

--23. (new) The compound of the formulae II according to claim 21, wherein:

$R^1$  is hydrogen,  $C_{1-3}$ -alkyl, *n*-butyl, isobutyl, *sec*-butyl, cyclopropyl,  $C_{1-3}$ -alkoxy, halogen, or  $-CF_3$ ;

$R^2$  is  $-NR^6R^7$ , wherein

$R^6$  is hydrogen,  $C_{1-4}$ -alkyl, or cyclopropyl,

$R^7$  is hydrogen or  $C_{1-4}$ -alkyl, or

$R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;

$R^3$  is hydrogen,  $C_{1-3}$ -alkyl, *n*-butyl, isobutyl, *sec*-butyl,  $C_{1-3}$ -alkoxy, halogen, or  $-CF_3$ ;

$R^4$  is hydrogen,  $C_{1-3}$ -alkyl, *n*-butyl, isobutyl, *sec*-butyl, or halogen; and,

$R^5$  is hydrogen,  $C_{1-3}$ -alkyl, *n*-butyl, isobutyl, *sec*-butyl,  $C_{1-3}$ -alkoxy, halogen, or  $-CF_3$ ;

or a pharmaceutically acceptable salt thereof.--

--24. (new) The compound of the formulae II according to claim 21, wherein:

$R^1$  is hydrogen or methyl;

$R^2$  is  $-NR^6R^7$ , wherein

$R^6$  is hydrogen or methyl,

$R^7$  is hydrogen or methyl, or

$R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;

$R^3$  is hydrogen, methyl, fluorine, chlorine, or bromine;

$R^4$  is hydrogen; and

$R^5$  is hydrogen, methyl, chlorine, or bromine;

or a pharmaceutically acceptable salt thereof.--

--25. (new) A compound selected from the group consisting of:

2-(3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(5-amino-2-chloro-4-dimethylamino-2-methylphenylimino)imidazolidine, and

2-(3-amino-2-methylphenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof.--